SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial is the dominant focus, with traders awaiting confirmation of the 80th death that triggers final analysis; the last disclosed count was 78, and speculation links the prolonged wait and company silence to possible ASH disclosures. Bulls interpret the delay as a potential sign of longer survival, while bears question the trial timeline and warn that the outcome remains uncertain; the debate accompanies a sharp share-price decline.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on Iovances lifileucel program is the main focus, especially mature frontline melanoma results for lifileucel plus pembrolizumab and early sarcoma findings. Traders highlight durable melanoma responses as supportive of expansion into earlier treatment, while others caution that the cohorts are small and the sarcoma response rate eased as the sample grew.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A broad selloff in AI neocloud stocks, driven by worries about debt, financing costs, and whether rapid data-center spending can earn adequate returns, has weighed on Nebius alongside peers. Traders are divided: bears see further valuation pressure, while bulls argue Nebius is better positioned than more leveraged rivals and view the drop as an overdone sector-wide move.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A Nasdaq-futures rebound around the 1987 Black Monday anniversary is dominating discussion after a steep tech-led selloff, with big-tech earnings ahead. Traders are split on whether the bounce is a durable recovery or a short-covering rally that could fade, while AI-stock weakness and broader market risks remain concerns.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after last weeks tech-led selloff has shifted the conversation to whether the bounce will hold, amid fears tied to the Black Monday anniversary. Bulls call it a relief rally or short squeeze and dismiss crash worries, while skeptics warn the move may fade; upcoming megacap earnings add to market focus.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Concern over IPO lockup expirations and the potential for insider-share selling is a recurring focus as CBRS faces a steep decline. Traders also point to weakness across AI and semiconductor stocks and question the companys high valuation, growth prospects, and reliance on OpenAI; others argue the selloff is overdone and are buying the dip.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

XBI is drawing attention amid a broad biotech selloff that traders link to rising yields, rate concerns, and rotation away from riskier small-cap names toward AI and other sectors. The community is split between viewing the decline as an oversold buying opportunity and warning that technical weakness and macro pressure could drive further losses.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys QNX growth storyparticularly a major Alloy Kore vehicle-platform design win and an Uber design win, alongside stronger results and a raised outlookis driving discussion. Bullish traders see potential in software-defined vehicles and physical AI, while skeptics question how quickly design wins will translate into revenue and note the share-price weakness.

GEOM maps the world's oil fields, mines, rare earths, and power plants, tracks what is and isn't tokenized, and cryptographically signs every dataset it publishes. Anyone can verify what we said and when. No account, no key, no permission. Sources include the WRI Global Power Plant Database and Global Energy Monitor (CC BY 4.0), attributed in full inside the app. Most of it already exists, spread across filings and terminals no one reads. GEOM gathers it and records where each figure came from.

GEOM

Attention centers on the proposed GEOM platform for tokenizing energy and mineral assets and royalties, which traders link to Greenland Energy and USFM; bullish holders are anticipating a platform demo, launch, or partner announcement. Others question the tokens verified utility and connections, citing thin liquidity, sharp swings, and rug-pull risk.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds upcoming Q3 report is the main focus, with traders weighing resilient revenue and past earnings beats against trimmed profit expectations and elevated jet-fuel costs. The recent decline and analyst target cuts have left sentiment split between dip-buyers and traders concerned about a miss or further post-earnings weakness.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veradermics to Hold Conference Call to Discuss Topline Results from Phase 3 304 Clinical Trial of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Monday, October 19, 2026, at 8:00 am ET to review results from...

Veradermics to Present at Upcoming September Investor Conferences

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that company management will participate in the following upcoming investor conferences in September: Wells...

Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent corporate and clinical...

Veradermics (MANE) Positioned to Disrupt Hair Loss Market

Veradermics?(MANE) Positioned to Disrupt Hair Loss Market...

Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study 302 in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced the presentation of data from the Phase 2/3 Study 302 of VDPHL01 in male patients with mild-to-moderate pattern...

Why Is MANE Stock Rising Today?

Equity

In Veradermics’ Phase 2 trial for VDPHL01, female subjects showed an increase in hair count as early as the second month of treatment.


Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months

Veradermics reported positive phase 2 data for VDPHL01, showing hair growth and favorable safety in women with pattern hair loss.read more...

PayPal, Veradermics, Alibaba And Other Big Stocks Moving Higher On Wednesday

US stocks close higher, Dow Jones up 100 points, PayPal shares rise on $53 billion acquisition proposal, other big gains from Aehr Test, Electrovaya, Robo.ai, Falcon's Beyond, Veradermics, Lucid Group, Kopin, MINISO, Mesoblast, Nexstar, Lionsgate, Karman.read more...

Veradermics Oral VDPHL01 Delivers Positive Study 207 Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study 306 Readout

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced positive topline results from its open-label Phase 2 clinical trial (Study 207) evaluating VDPHL01, a...

Veradermics to Hold Conference Call to Discuss Study 207 Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss

Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced it will host an investor call and live webcast on Wednesday, July 15, 2026 at 8:00 am ET to review results from...

Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

Veradermics Inc

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$108.82
Prev Close	$115.07
Open	$114.19
Dividend Yield	N/A
50-Day Moving Average	$109.26
Beta	-0.07
Avg. Volume	736,729.06
PE Ratio	N/A

52-Week High	$136.72
52-Week Low	$17.00
Market Capitalization	$4.55B
EPS (Annual)	-$2.23
Price to Book	5.58
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

MANE Fundamentals